Patient-derived microvesicles/AIE luminogen hybrid system for personalized sonodynamic cancer therapy in patient-derived xenograft models
نویسندگان
چکیده
منابع مشابه
Genomic Profiling of Patient-Derived Colon Cancer Xenograft Models
Recent evidence suggests that patient derived xenograft (PDX) models can maintain certain pathological and molecular features of the original disease. However, these characterizations are limited to immunohistochemistry or by tissue microarray analysis. We conducted a high-throughput sequencing of primary colon tumor and PDX has not been reported yet. Fresh primary colon cancer tissues that ori...
متن کاملNext generation patient-derived prostate cancer xenograft models
leading cause of cancer-related death of North American males.1 The disease is at present incurable once it has metastasized, and most deaths from this disease are due to metastases that are highly resistant to current conventional therapies. Prostate cancer is considered a multifocal disease that generally consists of a dominant cancer and one or more concurrent cancers of smaller volume with ...
متن کاملPatient-Derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment
Despite increasing evidence that precision therapy targeted to the molecular drivers of a cancer has the potential to improve clinical outcomes, high-grade epithelial ovarian cancer (OC) patients are currently treated without consideration of molecular phenotype, and predictive biomarkers that could better inform treatment remain unknown. Delivery of precision therapy requires improved integrat...
متن کاملPatient-derived xenograft models for oncology drug discovery
The success of targeted therapies for cancer patients rests on three major components: the right target(s), the right drug and drug combination, and the right patient population. Although much progress has been made in understanding the mechanism of disease and in refi ning pharmaceutical properties of therapeutic agents, the attrition rates between target discovery and drug marketing approval ...
متن کاملPersonalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
PURPOSE To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models. EXPERIMENTAL DESIGN We established 12 PDXs from BRAF inhibitor-progressed melanoma patients. Following expansion, PDXs were analyzed using targeted sequencing and reverse-phase protein arrays. By using multi-arm preclinical trial designs, we ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomaterials
سال: 2021
ISSN: 0142-9612
DOI: 10.1016/j.biomaterials.2021.120755